Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Reducing recurrence of large colorectal polyps after removal

Official title: Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps

Run by Centre hospitalier de l'Université de Montréal (CHUM) · NCT06271941 · Data updated 2026-11-12

This study is testing if a new method called hybrid argon plasma coagulation can help prevent large colorectal polyps from coming back after they've been removed, compared to the usual treatment.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment892 (estimated)
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
Academic / other
Locations1 site (Montreal, Quebec)
StatusRecruiting
StartedJuly 19, 2024
Main results expectedOctober 1, 2027
Study endsApril 1, 2028
Registry record updatedSeptember 18, 2026
Trial IDNCT06271941 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who are undergoing EMR for large colorectal laterally spreading lesions.

Probably not a fit

Patients with inflammatory bowel disease, poor general health, or those with invasive cancer in the polyp will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of hybrid argon plasma coagulation (h-APC) in reducing the recurrence of large colorectal polyps after endoscopic mucosal resection (EMR). Patients with large laterally spreading lesions (≥20mm) will be randomly assigned to receive either h-APC ablation or the standard snare tip soft coagulation (STSC) margin ablation. The trial aims to determine if the h-APC technique leads to lower rates of lesion recurrence compared to the current standard of care. Participants will undergo a standard colonoscopy preparation before the procedure, and the trial will be conducted at a single center in Montreal.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the recurrence of colorectal polyps, thereby lowering the risk of colorectal cancer.

How similar studies have gone: While the specific approach of h-APC is novel, similar techniques have shown promise in reducing recurrence in other studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* adult ≥18 years old
* patients undergoing EMR for a large (≥20mm) colorectal LSL
* patients providing written and informed consent for study participation.

Exclusion Criteria:

* inflammatory bowel disease;
* non-elective colonoscopy;
* poor general health (American Society of Anesthesiologists classification \>III);
* coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets \<50 x 109/L);
* pedunculated polyps (Paris class Ip, Isp);
* overt signs of deep submucosal invasive cancer (JNET 3);
* biopsy proven invasive carcinoma in a potential study polyp.
* Pregnant women

Where it's running

  • Centre Hospitalier de l'Université de Montréal
    Montreal, Quebec, Canada
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.